- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Chemical Biology
- ACRF Stem Cells and Cancer
- Bioinformatics
- Cancer and Haematology
- Cell Signalling and Cell Death
- Development and Cancer
- Immunology
- Infection and Immunity
- Inflammation
- Molecular Genetics of Cancer
- Molecular Immunology
- Molecular Medicine
- Population Health and Immunity
- Structural Biology
- Systems Biology and Personalised Medicine
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Partnering opportunities
- Opportunities in platform technologies
- A complete cure for HBV
- A stable efficacious Toxoplasma vaccine
- Activating SMCHD1 to treat FSHD
- Fut8 Sugar coating immuno oncology
- Intercepting inflammation with RIPK2 inhibitors
- Novel checkpoints NK cells emerge as key players in IO
- Precision epigenetics silencing SMCHD1 to treat Prader Willi Syndrome
- Rethinking CD52 a therapy for autoimmune disease
- Targeting plasmacytoid dendritic cells for systemic lupus erythematosus
- Treating Epstein-Barr virus associated malignancies
- Royalties distribution
- Start-up companies
- Partnering opportunities
- Collaborators
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Research fields
- Bioinformatics
- Cancer biology
- Cell death
- Cell signalling
- Clinical translation
- Computational biology
- Drug discovery
- Epigenetics
- Flow cytometry
- Genomics
- Haematology
- Imaging
- Immunology
- Infection
- Inflammation
- Medicinal chemistry
- Personalised medicine
- Proteomics
- Stem cells
- Structural biology
- Systems biology
- Vaccine development
- People
- Anne-Laure Puaux
- Associate Professor Aaron Jex
- Associate Professor Alyssa Barry
- Associate Professor Andrew Webb
- Associate Professor Anne Voss
- Associate Professor Chris Tonkin
- Associate Professor Daniel Gray
- Associate Professor Edwin Hawkins
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Murphy
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor Justin Boddey
- Associate Professor Marco Herold Marco Herold
- Associate Professor Marnie Blewitt
- Associate Professor Matthew Ritchie
- Associate Professor Mike Lawrence
- Associate Professor Nicholas Huntington
- Associate Professor Oliver Sieber
- Associate Professor Rachel Wong
- Associate Professor Sandra Nicholson
- Associate Professor Seth Masters
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Wai-Hong Tham
- Associate Professor Wei Shi
- Catherine Parker
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Ben Tran
- Dr Bob Anderson
- Dr Brad Sleebs
- Dr David Komander
- Dr Diana Hansen
- Dr Drew Berry
- Dr Emma Josefsson
- Dr Ethan Goddard-Borger
- Dr Gary Pitt
- Dr Gwo Yaw Ho
- Dr Hui-Li Wong
- Dr Hélène Jousset Sabroux
- Dr Ian Majewski
- Dr Ian Street
- Dr Jacqui Gulbis
- Dr James Vince
- Dr Jason Tye-Din
- Dr Joanna Groom
- Dr John Wentworth
- Dr Julie Mercer
- Dr Kate Sutherland
- Dr Kelly Rogers
- Dr Ken Pang
- Dr Leanne Robinson
- Dr Leigh Coultas
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Marie-Liesse Asselin-Labat
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Melissa Call
- Dr Melissa Davis
- Dr Michael Low
- Dr Misty Jenkins
- Dr Peter Czabotar
- Dr Philippe Bouillet
- Dr Priscilla Auyeung
- Dr Rhys Allan
- Dr Ruth Kluck
- Dr Samar Ojaimi
- Dr Samir Taoudi
- Dr Sant-Rayn Pasricha
- Dr Shalin Naik
- Dr Sheau Wen Lok
- Dr Simon Chatfield
- Dr Stephen Wilcox
- Dr Tracy Putoczki
- Guillaume Lessene
- Helene Martin
- Keely Bumsted O'Brien
- Mr Joel Chibert
- Mr Simon Monard
- Mr Stan Balbata
- Mr Steve Droste
- Ms Carolyn MacDonald
- Ms Samantha Ludolf
- Ms Wendy Hertan
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Clare Scott
- Professor David Huang
- Professor David Vaux
- Professor Doug Hilton
- Professor Gabrielle Belz
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor Jane Visvader
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leonard C Harrison
- Professor Li Wu
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Melanie Bahlo
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Burgess
- Professor Tony Papenfuss
- Professor Warren Alexander
- Education
- PhD
- Honours
- Masters
- Undergraduate
- Student research projects
- 3D and 4D imaging of thymic T cell differentiation
- Activating https://www.wehi.edu.au/node/add/individual-student-research-page#Parkin to treat Parkinson’s disease
- Activation, regulation, and biological roles of E3 ubiquitin ligases
- Bioinformatics methods for detecting and making sense of somatic genomic rearrangements
- Characterising regulatory T cells in coeliac disease
- Computational melanoma genomics
- Deep profiling of blood cancers during targeted therapy
- Defining the role of necroptosis in platelet production and function
- Determining the migration signals leading to protective immune responses
- Developing mucolytics to treat chronic respiratory diseases
- Developing new tools to visualise necroptotic cell death
- Development of live-cell, automated microscopy techniques for studying malaria
- Development of tools to inform malaria vaccine design
- Discovering new genetic causes of primary antibody deficiencies
- Discovery of novel drug combinations for the treatment of bowel cancer
- Dissecting the induction and integration of T cell migration cues
- Drug targets and compounds that block growth of malaria parasites
- Effects of nutrition on immunity and infection in Asia and Africa
- Eosinophil and neutrophil heterogeneity
- Eosinophil maturation
- Epigenetic regulation of systemic iron homeostasis
- Functional differences between young and old platelets
- Generation of cytokine antagonists
- Genetic dissection of mechanisms of Plasmodium invasion
- Genomic characterisation of epigenetic regulators involved in X inactivation
- High resolution 3-dimensional imaging to characterise metastatic cancers
- High-resolution imaging of host cell invasion by the malaria parasite
- Home renovations: understanding how Toxoplasma redecorates its host cell
- How the epigenetic regulator SMCHD1 works and how to target it to treat disease
- Human monoclonal antibodies against malaria infection
- Identification of malaria parasite entry receptors
- Identification of new therapeutic opportunities for pancreatic cancer
- Identifying disease-causing haplotypes with hidden Markov models
- Interleukin-11 in gastrointestinal bacterial infections
- Investigating mechanisms of cell death and survival using zebrafish
- Investigating new paths to selective modulation of potassium channels
- Let me in! How Toxoplasma invades human cells
- Long-read sequencing for transcriptome and epigenome analysis
- Macro-evolution in cancer
- Mapping DNA repair networks in cancer
- Mapping how multiple malaria episodes are related
- Modelling gene regulatory systems
- Modulation of immune responses by immunosuppressive chemokines
- Molecular basis for inherited Parkinson’s disease mechanism of PINK1
- Mucus at the molecular level
- Novel cell death and inflammatory modulators in lupus
- Plasmodium vivax host-parasite interactions: impact on immunity
- Predicting drug response in cancer
- Programming T cells to defend against infections
- Reconstructing the immune response: from molecules to cells to systems
- Regulation of cytokine signalling
- Screening for regulators of jumping genes
- Target identification of potent antimalarial agents
- Targeting the immune system in cancer
- The role of interleukin-11 in acute myeloid leukaemia
- Transmembrane control of type I cytokine receptor activation
- Uncovering the roles of long non-coding RNAs in human bowel cancer
- Understanding retinal eye diseases with retinal transcriptomic data analysis
- Understanding the role of stromal cells in pancreatic cancer growth
- Unravelling the tumour suppressor network in models of lung cancer
- Utilising pre-clinical models to discover novel therapies for tuberculosis
- Zombieland: evolution of a dead enzyme that kills cells by necroptosis
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Casey Ah-Cann
- Catia Pierotti
- Charlotte Slade
- Daniel Cameron
- Emma Nolan
- Jason Brouwer
- Joy Liu
- Lucille Rankin
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Sarah Garner
- Simona Seizova
- Michael Low
- Sofonias Tessema
- Santini Subramaniam
- Miles Horton
- Alexandra Gurzau
- Tamara Marcus
- Nicholas Chandler
- Student achievements
- Student association
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
Scientist receives $200K to study genetic causes of multiple myeloma
6 October 2011
has been awarded an MMRF grant to study the role of immune cell genes
in multiple myeloma.
Walter and Eliza Hall Institute researcher Professor Stephen Nutt has been awarded a $200,000 Multiple Myeloma Research Foundation (MMRF) grant to study key immune cell genes and their role in cancer.
It is hoped that the research will lead to the identification of new therapeutic targets for the difficult-to-treat blood cancer multiple myeloma.
The MMRF Senior Research Grants aim to accelerate the development of therapeutic approaches for myeloma. Multiple myeloma is one of the most common blood cancers, and arises from altered plasma cells whose numbers can no longer be appropriately controlled.
Dr Nutt, who heads the institute's Molecular Immunology division, said that he was excited about the potential of the research, made possible with the MMRF funding.
“Plasma cells are a rare and highly specialised cell type which produce the antibodies that are essential to protect us from microorganisms and delivery immunity after vaccination,” Dr Nutt said. “They are also at the origin of multiple myeloma. Our research aims to understand how plasma cells are formed and what goes wrong with these cells to produce multiple myeloma.”
Dr Nutt studies the function of molecules called transcription factors, which control the development, differentiation and function of immune cells. Transcription factors bind to DNA sequences to control which genes are switched on or off in a cell, which affects protein production. Modern genomics technologies have revealed that altered transcription factor functions are at the heart of most blood cell cancers.
Two particularly important transcription factors for the development of plasma cells, Irf4 and Blimp1, will be the first to have their role in multiple myeloma investigated, Dr Nutt said.
“We know that the production of plasma cells is regulated by the genes Irf4 and Blimp1 although we don't know how this works,” Dr Nutt said. “In this project, we will use sophisticated DNA screening technologies in an attempt to understand how Irf4 and Blimp1 control the activity of the plasma cell genome. There is evidence to suggest that these proteins are essential for development of multiple myeloma, and we are interested in seeing whether inhibiting Irf4 or Blimp1 function impairs the growth of the tumour.”
Dr Nutt said that while multiple myeloma can be treated with chemotherapy, there is at present no therapy that is specific for this type of cancer, and no cure.
“Our studies, if successful, will highlight Irf4 and or Blimp1 as important therapeutic targets for this disease,” he said.
Institute director Professor Doug Hilton said that the new research coming out of the division is very exciting. “The work from the Molecular Immunology division has the potential to open up new avenues of treatment for multiple myeloma and builds on the tremendous success of the institute in tackling a variety of blood cell cancers,” he said.
For further information:
Liz Williams
Communications and Marketing Officer
Ph: +61 3 9345 2928
Mob: 0405 279 095
Email: williams@wehi.edu.au